Novel anti-inflammatory agents Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009
LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
The pharmacological and safety profile of a novel selective phosphodiesterase-4(PDE4) inhibitor:- GRC- 3886 Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Ovalbumin-induced asthma model in Brown Norway rats demonstrates potential anti-asthmatic effects of Neu-164, a novel antioxidant and anti-inflammatory compound Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
Pharmacological properties of a novel PI3Kd inhibitor, DS-1515 Source: International Congress 2018 – Basic pharmacology Year: 2018
Anti-inflammatory properties of synthetic and endogenous Rev-Erb-alpha agonists. Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019
In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Anti-inflammatory, antioxidant and immunomodulatory effects of curcumin in sensitized rat Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015